NAVB Navidea Biopharmaceuticals
- 0.038
- +0.000+0.27%
Navidea Biopharmaceuticals News
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend Its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel a
Navidea Settles Litigation With Capital Royalty, Stock Rallies 30%
Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.DUBLIN, Ohio--(BUSINESS WIRE)--Na
Sector Update: Health Care
Health care stocks were rising late Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each up about 1.2%. The iShares Biotechnology ETF (IBB) was addin
Top Midday Decliners
OmniQ (OMQS) shares slumped 48% after the company said it priced an underwritten public offering of 3 million common shares, or pre-funded warrants in lieu of common shares, at $1 per share for gross
Navidea Biopharmaceuticals Faces Delisting From NYSE American, Plans to Move to OTC Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersLongeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 172.7% to $0.01 during Tuesday's pre-market session. Avinger (NASDAQ:AVGR) shares rose 47.61% to $8.96. The company's mar
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPhenomeX (NASDAQ:CELL) shares increased by 136.4% to $0.95 during Thursday's regular session. As of 13:31 EST, PhenomeX's stock is trading at a volume of 19.6 million, which is 2758.8% of its a
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Following the Company's Fix, Fund, Propel approach, Navidea formally submitted a request for an oral hearing with New York Stock Exchange American (NYSE American) Hearing Panel to appeal potential delisting of its stock
Why Navidea Biopharmaceuticals Shares Are Nosediving
Navidea Biopharmaceuticals Inc (NASDAQ:NAVB) shares are trading lower by 18.5% to $0.08 after the company announced NYSE American has commenced delisting proceedings and the company intends to appeal.
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Following the Company's Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from the N
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) shares increased by 26.6% to $3.33 during Monday's pre-market session. The company's market cap stands at $2.8 million. Better Therapeutics (NASDAQ:BTTX) sha
Navidea Biopharmaceuticals Received Written Notification That NYSE Is Determined To Commence Proceedings To Delist The Company's Stock; The Company's Board Will Appeal The Determination To Commence Delisting Proceedings
Navidea Biopharmaceuticals Received Written Notification That NYSE Is Determined To Commence Proceedings To Delist The Company's Stock; The Company's Board Will Appeal The Determination To Commence De
12 Health Care Stocks Moving In Friday's After-Market Session
GainersIntelligent Bio Solutions (NASDAQ:INBS) stock rose 8.6% to $2.14 during Friday's after-market session. The company's market cap stands at $4.9 million. MSP Recovery (NASDAQ:LIFW) shares increas
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of
Express News | Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA As Chief Financial Officer >NAVB
Express News | Navidea Biopharma Names Dana J Moss to Board; Amit Bhalla Steps Down
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
In line with the Company's Fix, Fund, Propel approach, Dana J Moss, JD joins Navidea's Board, adding depth in legal advice, strategic business, life sciences and technology in support of stated strategy to advance innovative technology to market. Separately, Amit Bhalla steps down from Board.
Express News | Navidea Biopharmaceuticals Rejects Unsolicited Offer From ProPhase Labs to Acquire Certain Assets
Analysis
Price Target
No Data
